Evidence map›Paper›PMID 37887546›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.

Taylor E Woo, Igor Stukalin, Philip Q Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Winson Y Cheung, Daniel Y C Heng, Tina Cheng

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Taylor E WooDepartment of Medicine, Division of Dermatology, University of Calgary, Calgary, AB T2N 1N4, Canada.
Igor StukalinDepartment of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.
Philip Q DingDepartment of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.ORCID 0000-0002-0413-5485
Siddhartha GoutamDepartment of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.ORCID 0000-0002-5398-2357
Michael SanderDepartment of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.ORCID 0000-0002-6250-5368
Benjamin EwanchukDepartment of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.ORCID 0000-0001-6197-9222
Winson Y CheungDepartment of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.
Daniel Y C HengDepartment of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.
Tina ChengDepartment of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.ORCID 0000-0002-6399-0844
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MelanomaSkin NeoplasmsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChildChild, PreschoolCutaneous Malignant MelanomaFemaleHumansImmune Checkpoint InhibitorsIpilimumabMaleMiddle AgedImmune Checkpoint InhibitorsIpilimumabNivolumabageimmune checkpoint inhibitoripilimumab plus nivolumabmelanomanivolumabolder adultspembrolizumabsurvival

Identifiers

PMID37887546
PMCPMC10605250
OpenAlexW4387264700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.